Healthcare Providers and Services
Company Overview of Ameritox, Ltd.
Ameritox, Ltd. develops pain medication monitoring solutions for behavioral health clinicians in the United States. It offers laboratory services and practice management tools; Rx GuardianCD, a urine drug monitoring solution that helps clinicians to identify potential abuse, misuse, or diversion of patient medication; Rx Guardian INSIGHT Report, which provides physicians with a view of their chronic pain patient’s medication monitoring results; and Rx Guardian results report that provides information available on patient’s pain medication use in easy-to-read format. The company also provides clinical staff training and support, results interpretation and support, contract and payer partnersh...
300 East Lombard Street
Baltimore, MD 21202
Founded in 1996
Key Executives for Ameritox, Ltd.
Chief Laboratory Officer and Senior Vice President
Vice President of Intellectual Property & Program Development
Vice President of Public Relations
Vice Chairman and Special Advisor
Compensation as of Fiscal Year 2016.
Ameritox, Ltd. Key Developments
Ameritox Research Shows Wide Variety of Potential Misuse and Abuse of Other Medications and Drugs in Those Prescribed Opioids
Sep 11 15
Ameritox has released a new clinical research study illustrating an emerging trend within the raging epidemic of prescription opioid misuse and abuse sweeping the country: abuse of non-prescribed opioids, medications used to treat behavioral health conditions, and illicit drugs in those prescribed opioid therapy. Study results revealed tens of thousands of patients being treated with opioid therapy as testing positive for non-prescribed, powerful opioids like oymorphone, non-prescribed benzodiazepines like Xanax and illicit drugs such as cocaine and heroin. Of more than 970,000 urine samples analyzed from patients each prescribed an opioid medication, nearly 17% tested positive for non-prescribed antidepressants and 14% contained non-prescribed benzodiazepines. In additional, almost 12% of the samples tested positive for non-prescribed opiates, 2% for non-prescribed amphetamines, 1.7% for cocaine and 1% for heroin, among other medications and drugs.
Ingenuity Health Expands Reference Database to Help Assess Medication Adherence in Those with Serious Mental Illness
Jul 14 15
Ingenuity Health, a service of Ameritox Ltd. expanded its comprehensive reference database that helps clinicians assess medication adherence among patients with Serious Mental Illness. Ingenuity Health has developed a method to help assess adherence in patients prescribed the antipsychotic drug lurasidone, marketed under the brand name Latuda®. The reference database provides behavioral health clinicians help in addressing the ongoing problem of medication non-adherence in those with SMI.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries